

STATEMENT FROM INVIDIOR 2ND JULY

Attributable to an INVIDIOR spokesperson

Indivior has made the commercial decision to discontinue the marketing and sale of SUBLOCADE® (buprenorphine modified release solution for injection) in Australia. SUBLOCADE is a once-monthly injectable treatment for opioid addiction administered by a healthcare provider.

Indivior is committed to maintaining sufficient supply of SUBLOCADE to support patient continuity of care in Australia until the proposed last reimbursement claim date of 31 December 2026. Indivior intends to work with the appropriate authorities and experts in Australia to ensure an orderly transition that minimizes disruption.

There are alternatives to SUBLOCADE widely available in Australia. Medicines approved in Australia for the treatment of opioid dependence include methadone and buprenorphine and they are currently available in a variety of formulations and brands.